BWAY Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

15.680

Open

15.650

VWAP

15.10

Vol

72.63K

Mkt Cap

601.14M

Low

14.650

Amount

1.10M

EV/EBITDA(TTM)

79.51

Total Shares

40.13M

EV

585.29M

EV/OCF(TTM)

42.88

P/S(TTM)

10.78

Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

Show More

Events Timeline

(ET)

2026-06-29

08:00:00

BrainsWay Presents New Data on Deep TMS for PTSD and Depression

2026-05-18 (ET)

2026-05-18

07:50:00

BrainsWay Enters Strategic Financing Agreement with APS Innovations

2026-05-13 (ET)

2026-05-13

07:50:00

BrainsWay Q1 Revenue $15.53M, Exceeds Consensus

2026-05-13

07:50:00

BrainsWay Expects FY26 Adjusted EBITDA of $12M-$14M

2026-03-19 (ET)

2026-03-19

08:00:00

BrainsWay Completes $1M Investment in Axis

2026-03-11 (ET)

2026-03-11

16:30:00

Dow and S&P 500 Close Lower Amid Oil Price Volatility

2026-03-11

12:00:00

Dow Jones Drops Over 400 Points Amid Oil Price Volatility

2026-03-11

07:40:00

BrainsWay Q4 Revenue $14.5M, Exceeds Consensus

News

Newsfilter

06-29Newsfilter

BrainsWay Presents Positive Data on PTSD and Depression Treatment

Newsfilter

06-22Newsfilter

BrainsWay Expands TMS Coverage Policies Across U.S.

Newsfilter

06-09Newsfilter

BrainsWay Presents New Durability Data for Deep TMS in Depression Treatment

Newsfilter

05-18Newsfilter

BrainsWay Enters Strategic Equity Financing Agreement with Hopemark

Yahoo Finance

05-13Yahoo Finance

BrainsWay Ltd Reports Strong Q1 2026 Earnings Growth

seekingalpha

05-13seekingalpha

BrainsWay Q1 Earnings Beat Expectations with Strong Guidance

3 Analyst Rating

Wall Street analysts forecast BWAY stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

19.00

Averages

26.33

High

30.00

Current: 0.000

Low

19.00

Averages

26.33

High

30.00

H.C. Wainwright

Raghuram Selvaraju

Buy

maintain

$15 -> $17

AI Analysis

2026-05-26

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$15 -> $17

AI Analysis

2026-05-26

maintain

Buy

Reason

H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Brainsway to $17 from $15 and keeps a Buy rating on the shares following the Q1 report. The firm cites its higher forward revenue estimates as well as an increase in the perceived value of the company's convertible loan investment in Neurolief for the target boost.

H.C. Wainwright

Buy

downgrade

$30 -> $15

2026-03-12

Reason

H.C. Wainwright

Price Target

$30 -> $15

2026-03-12

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Brainsway to $15 from $30 and keeps a Buy rating on the shares to reflect the recent change effected in the ratio of American Depositary Shares to ordinary shares. Previously, this ratio was one ADS for every two ordinary shares, but earlier this month it was revised to a one-to-one ratio, the analyst noted. In the wake of a "solid performance in 2025, the firm sees a positive medium- to long-term outlook, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BWAY

Unlock Now

Valuation Metrics

The current forward P/E ratio for Brainsway Ltd (BWAY.O) is 36.10, compared to its 5-year average forward P/E of 41.31. For a more detailed relative valuation and DCF analysis to assess Brainsway Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

41.31

Current PE

36.10

Overvalued PE

127.81

Undervalued PE

-45.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

4.97

Current EV/EBITDA

46.97

Overvalued EV/EBITDA

19.57

Undervalued EV/EBITDA

-9.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.49

Current PS

7.56

Overvalued PS

5.18

Undervalued PS

1.79

Financials

AI Analysis

Annual

Quarterly

Whales Holding BWAY

More Investment House Ltd.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Brainsway Ltd (BWAY) stock price today?

The current price of BWAY is 14.98 USD — it has decreased -6.49

What is Brainsway Ltd (BWAY)'s business?

Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

What is the price predicton of BWAY Stock?

Wall Street analysts forecast BWAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BWAY is26.33 USD with a low forecast of 19.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Brainsway Ltd (BWAY)'s revenue for the last quarter?

Brainsway Ltd revenue for the last quarter amounts to 15.53M USD, increased 34.63

What is Brainsway Ltd (BWAY)'s earnings per share (EPS) for the last quarter?

Brainsway Ltd. EPS for the last quarter amounts to 0.06 USD, increased 200.00

How many employees does Brainsway Ltd (BWAY). have?

Brainsway Ltd (BWAY) has 129 emplpoyees as of July 08 2026.

What is Brainsway Ltd (BWAY) market cap?

Today BWAY has the market capitalization of 601.14M USD.